1. Home
  2. OCUL vs WSBCO Comparison

OCUL vs WSBCO Comparison

Compare OCUL & WSBCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OCUL
  • WSBCO
  • Stock Information
  • Founded
  • OCUL 2006
  • WSBCO N/A
  • Country
  • OCUL United States
  • WSBCO United States
  • Employees
  • OCUL N/A
  • WSBCO N/A
  • Industry
  • OCUL Biotechnology: Pharmaceutical Preparations
  • WSBCO Major Banks
  • Sector
  • OCUL Health Care
  • WSBCO Finance
  • Exchange
  • OCUL Nasdaq
  • WSBCO Nasdaq
  • Market Cap
  • OCUL 2.3B
  • WSBCO 2.5B
  • IPO Year
  • OCUL 2014
  • WSBCO N/A
  • Fundamental
  • Price
  • OCUL $12.24
  • WSBCO $25.62
  • Analyst Decision
  • OCUL Strong Buy
  • WSBCO
  • Analyst Count
  • OCUL 10
  • WSBCO 0
  • Target Price
  • OCUL $22.33
  • WSBCO N/A
  • AVG Volume (30 Days)
  • OCUL 2.1M
  • WSBCO N/A
  • Earning Date
  • OCUL 11-04-2025
  • WSBCO N/A
  • Dividend Yield
  • OCUL N/A
  • WSBCO N/A
  • EPS Growth
  • OCUL N/A
  • WSBCO N/A
  • EPS
  • OCUL N/A
  • WSBCO N/A
  • Revenue
  • OCUL $55,783,000.00
  • WSBCO N/A
  • Revenue This Year
  • OCUL N/A
  • WSBCO N/A
  • Revenue Next Year
  • OCUL $17.75
  • WSBCO N/A
  • P/E Ratio
  • OCUL N/A
  • WSBCO N/A
  • Revenue Growth
  • OCUL N/A
  • WSBCO N/A
  • 52 Week Low
  • OCUL $5.79
  • WSBCO N/A
  • 52 Week High
  • OCUL $13.85
  • WSBCO N/A
  • Technical
  • Relative Strength Index (RSI)
  • OCUL 59.26
  • WSBCO N/A
  • Support Level
  • OCUL $11.08
  • WSBCO N/A
  • Resistance Level
  • OCUL $12.03
  • WSBCO N/A
  • Average True Range (ATR)
  • OCUL 0.53
  • WSBCO 0.00
  • MACD
  • OCUL 0.13
  • WSBCO 0.00
  • Stochastic Oscillator
  • OCUL 89.86
  • WSBCO 0.00

About OCUL Ocular Therapeutix Inc.

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Share on Social Networks: